Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENGPHARMACEUTICALCO., LTD.
Securities code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) securities abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Announcement No.: 2022024
Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
Announcement on election of chairman and appointment of general manager
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as “the company”) on 2022
On March 4, 2022, the fourth interim meeting of the Fifth Board of directors was held, which was deliberated and passed
After the proposal on the by election of the chairman of the 5th board of directors, the proposal on the appointment of the general manager of the company and the proposal on the by election of the members of the strategic development committee of the 5th board of directors, Ms. Zhou Xiaoli was elected as the chairman of the 5th board of directors and the director of the strategic development committee of the company, and Ms. Zhou Xiaoli was appointed as the general manager of the company, The term of office expires at the expiration of the current board of directors.
It is hereby announced
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) board of directors
March 6, 2022
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENGPHARMACEUTICALCO., LTD.
Attachment: resumes of the chairman, general manager and director of the strategic development committee of the board of directors
Zhou Xiaoli: female, born in 1973, Chinese nationality, without overseas residency, college degree. He has successively served as the manager of the marketing department of Guangdong Ruixing Pharmaceutical Co., Ltd. and the assistant to the chairman of the company. He is currently the supervisor of Shanghai Yuwei Semiconductor Technology Co., Ltd., the executive director of Hunan fangshengtang Pharmaceutical Co., Ltd., the executive director of Hainan Boda Pharmaceutical Co., Ltd., the director, director and deputy general manager of Chongqing xiaopanda Pharmaceutical Co., Ltd.
Ms. Zhou Xiaoli has been engaged in the pharmaceutical industry for more than 20 years and has rich experience in enterprise management and drug sales. Ms. Zhou Xiaoli has the qualifications and working experience to perform the duties of chairman and general manager. She has not found any situation that she is not allowed to be a senior manager of the company as stipulated in the company law, the stock listing rules of Shanghai Stock Exchange and the articles of association, or that she has been determined as a market prohibited person by the CSRC and the prohibition has not been lifted.
